Arylpiperazines having activity at the serotonin 1A receptor
AssigneeEli Lilly and Company
InventorsDaniel Timothy Kohlman, Yao-Chang Xu
Life of this patent
Estimating the term…
Abstract
A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal.
Claims6
A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of a compound of the formula:
- or the pharmaceutically acceptable salts thereof.
A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or the pharmaceutically acceptable salts thereof.
A method of treating anxiety comprising administering to a patient in need of such treatment an effective amount (+)-1-(2-methoxyphenyl)4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or the pharmaceutically acceptable salts thereof.
A method of treating depression comprising administering to a patient in need of such treatment an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or the pharmaceutically acceptable salts thereof.
A method of assisting a patient in ceasing or reducing their use of tobacco or nicotine comprising administering to a patient an effective amount of a compound of the formula
- or the pharmaceutically acceptable salts thereof.
A method of assisting a patient in ceasing or reducing their use of tobacco or nicotine comprising administering to a patient an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or the pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.